S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
The Next Big Crisis Is Here (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
The Next Big Crisis Is Here (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
The Next Big Crisis Is Here (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
The Next Big Crisis Is Here (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks

Arbutus Biopharma - ABUS Stock Forecast, Price & News

$2.93
+0.06 (+2.09%)
(As of 01/26/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.86
$2.96
50-Day Range
$2.22
$2.93
52-Week Range
$1.85
$3.64
Volume
409,583 shs
Average Volume
843,843 shs
Market Capitalization
$439.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.50

Arbutus Biopharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
121.8% Upside
$6.50 Price Target
Short Interest
Healthy
3.14% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.88mentions of Arbutus Biopharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.46) to ($0.58) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

Medical Sector

853rd out of 1,048 stocks

Pharmaceutical Preparations Industry

423rd out of 513 stocks


ABUS stock logo

About Arbutus Biopharma (NASDAQ:ABUS) Stock

Arbutus Biopharma Corp. is a biopharmaceutical company. It engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.

Receive ABUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter.

ABUS Stock News Headlines

Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Update
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
TRADING JABS
Become an Investor in Brooklyn Gin
Award winning super-premium craft gin and upcoming Brooklyn distillerypixel
Arbutus to Participate in September Investor Conferences
See More Headlines
Receive ABUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter.

ABUS Company Calendar

Last Earnings
11/09/2022
Today
1/26/2023
Next Earnings (Estimated)
3/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABUS
Employees
85
Year Founded
1992

Price Target and Rating

Average Stock Price Forecast
$6.50
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+121.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-76,250,000.00
Net Margins
-191.34%
Pretax Margin
-178.99%

Debt

Sales & Book Value

Annual Sales
$10.99 million
Book Value
$1.17 per share

Miscellaneous

Free Float
142,154,000
Market Cap
$439.36 million
Optionable
Optionable
Beta
2.13

Social Links


Key Executives

  • William H. Collier
    President, Chief Executive Officer & Director
  • Michael J. McElhaugh
    Chief Operating Officer
  • David C. Hastings
    Chief Financial & Accounting Officer
  • Michael J. Sofia
    Chief Scientific Officer
  • Elizabeth Howard
    Secretary, Chief Compliance Officer & EVP













ABUS Stock - Frequently Asked Questions

Should I buy or sell Arbutus Biopharma stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ABUS shares.
View ABUS analyst ratings
or view top-rated stocks.

What is Arbutus Biopharma's stock price forecast for 2023?

4 brokerages have issued 1 year price targets for Arbutus Biopharma's shares. Their ABUS share price forecasts range from $5.00 to $9.00. On average, they expect the company's stock price to reach $6.50 in the next twelve months. This suggests a possible upside of 121.8% from the stock's current price.
View analysts price targets for ABUS
or view top-rated stocks among Wall Street analysts.

How have ABUS shares performed in 2023?

Arbutus Biopharma's stock was trading at $2.33 at the start of the year. Since then, ABUS stock has increased by 25.8% and is now trading at $2.93.
View the best growth stocks for 2023 here
.

When is Arbutus Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our ABUS earnings forecast
.

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma Co. (NASDAQ:ABUS) posted its quarterly earnings data on Wednesday, November, 9th. The biopharmaceutical company reported ($0.12) EPS for the quarter, hitting analysts' consensus estimates of ($0.12). The biopharmaceutical company had revenue of $5.95 million for the quarter, compared to analyst estimates of $11.12 million. Arbutus Biopharma had a negative net margin of 191.34% and a negative trailing twelve-month return on equity of 43.44%.

What is Mark J. Murray's approval rating as Arbutus Biopharma's CEO?

6 employees have rated Arbutus Biopharma Chief Executive Officer Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among the company's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arbutus Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), TherapeuticsMD (TXMD) and Novavax (NVAX).

What is Arbutus Biopharma's stock symbol?

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

Who are Arbutus Biopharma's major shareholders?

Arbutus Biopharma's stock is owned by many different institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.55%) and Clear Harbor Asset Management LLC (0.04%).
View institutional ownership trends
.

How do I buy shares of Arbutus Biopharma?

Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arbutus Biopharma's stock price today?

One share of ABUS stock can currently be purchased for approximately $2.93.

How much money does Arbutus Biopharma make?

Arbutus Biopharma (NASDAQ:ABUS) has a market capitalization of $439.36 million and generates $10.99 million in revenue each year. The biopharmaceutical company earns $-76,250,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis.

How can I contact Arbutus Biopharma?

Arbutus Biopharma's mailing address is 701 VETERANS CIRCLE, WARMINSTER PA, 18974. The official website for the company is www.arbutusbio.com. The biopharmaceutical company can be reached via phone at (267) 469-0914, via email at ir@arbutusbio.com, or via fax at 604-419-3201.

This page (NASDAQ:ABUS) was last updated on 1/27/2023 by MarketBeat.com Staff